EcoDrugPlus

Nischarin

Ensembl ID : ENSPKIG00000025174
Gene Symbol: NISCH
2 Cross references
207 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSPKIG00000009929
Gene Symbol: NOS2
3 Cross references
165 Possible Orthologues:

Nociceptin Receptor-Like

Ensembl ID : ENSPKIG00000019824
Gene Symbol: LOC111851102
3 Cross references
189 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSPKIG00000014821
Gene Symbol: NOTCH1
3 Cross references
264 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSPKIG00000016569
Gene Symbol: NFKB1
4 Cross references
198 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSPKIG00000022873
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSPKIG00000000964
Gene Symbol: NR1H3
4 Cross references
389 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSPKIG00000011818
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSPKIG00000024131
Gene Symbol: NR3C1
2 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSPKIG00000024489
Gene Symbol: NR3C1
2 Cross references
203 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPKIG00000016396
Gene Symbol: NR3C2
4 Cross references
210 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPKIG00000016457
Gene Symbol: NR3C2
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).